Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
Price : $35 *
At a glance
- Drugs DCBCI 0901 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Standard Chemical & Pharmaceutical Company
- 04 Oct 2017 Status changed from recruiting to discontinued.
- 01 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2014 New trial record